Priveterra Acquisition Corp.
Status: Deal Closed
U=S+W/3
W=S@11.5
| IPO Proceeds, $M | $276.00M |
|---|---|
| IPO Date | Feb 9, 2021 |
| CEO | Robert Palmisano |
| Left Lead | Wells Fargo |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 + 6 |
| IPO Sector |
Healthcare
Medical technology |
| IPO Geography | Global |
| Target Company | AEON Biopharma |
| Deal Announced | Dec 13, 2022 |
| Deal Size, $M | $220.80M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Jul 3, 2023 |
| Amendment Vote | Feb 10, 2023 |
| Closing Date | Jul 21, 2023 |
Formerly PMGM
AEON
AEON/W
| Price | $0.56 |
|---|---|
| Last closing price | $0.58 |
| H/L, today | $0.55 / $0.60 |
| H/L, 52-week | $3.37 / $11.88 |
| Volume, today | 100,149 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Priveterra Acquisition Corp.:
- Structure and cap table
- 7 directors & officers
- 44 filings and events
- 3 underwriters
- 3 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Robert Palmisano | 76 | Chairman and Chief Executive Officer |
| Vikram Malik | 58 | President and Director |
| Oleg Grodnensky | 43 | Chief Operating Officer and Chief Financial Officer |
| David Meredith | 52 | Chief Legal Officer and Secretary |
| Lance A. Berry | 48 | Director |
| James A. Lightman | 62 | Director |
| Julie B. Andrews | 49 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Wells Fargo | Joint BR | 11,520,000 | units |
| Guggenheim Securities | Joint BR | 9,360,000 | |
| Odeon Capital Group | 3,120,000 | ||
| 24,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.